CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 209 enrolled
Drug / intervention
Comparator: raltegravirdrug
Likely dose
Comparator: raltegravir 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00764946
NCT00764946Phase 3Completed
CompareCT.gov

A Phase III Open-Label Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of MK0518/Raltegravir in a Diverse Cohort of HIV-Infected Patients

Merck Sharp & Dohme LLC·interventional·Posted Oct 2, 2008·Updated Mar 21, 2017

In Brief

A Phase 3 clinical trial evaluating Comparator: raltegravir for Human Immunodeficiency Virus. Completed, enrolled 209 participants.

Detailed Summary

A study to test the safety and effect of twice daily raltegravir in a diverse cohort of patients currently infected with human immunodeficiency virus (HIV), where at least 50% are African American and at least 25% are female, either having received antiretroviral drugs before or not.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2, 2008
Enrollment StartOct 1, 2008
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.8 years ago

Interventions

Comparator: raltegravirdrug

400 mg tablets taken twice daily. Total treatment period is 48 weeks.